FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
As RFK Jr.‘s hearings begin, so will scrutiny on his familiarity with key health programs
The job Robert F. Kennedy Jr. is seeking is defined by the task of overseeing Medicare and Medicaid, which he's shown little ...
WXYZ2m
Caroline Kennedy calls her cousin RFK Jr a 'predator' ahead of his senate confirmation hearings
Caroline Kennedy urged senators to reject her cousin, Robert F. Kennedy Jr., as President Donald Trump’s nomination to lead ...
United Therapeutics president sells shares worth $3.7 million
Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock ...
Hoodline13m
Cedar Park Woman Sentenced to Probation for Smuggling Unapproved Feline Drug, Forfeits $4 Million in Assets
A Cedar Park woman was sentenced to probation for illegally smuggling an unapproved cat medicine into the U.S. and selling it ...
Trump Order Didn’t Reverse All of Biden’s Measures to Lower Drug Costs
President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for ...
The American Journal of Managed Care46m
FDA Expands Semaglutide Use for CV, Kidney Risks in T2D, CKD
The latest semaglutide (Ozempic; Novo Nordisk) approval is set to tackle a major need for patients with both type 2 diabetes ...
Becker's Hospital Review33m
Vizient: Expect 3.84% increase in hospital pharmacy spend
Vizient forecasts a 3.84% rise in pharmacy spending for health systems and ambulatory surgery centers, driven by specialty and personalized medicines.